This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D67 (hereditary factor IX deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hemophilia B, Christmas disease, plasma thromboplastin component deficiency (PTC deficiency), hereditary coagulation factor IX deficiency, Hemophilia B, Congenital factor IX deficiency |
| C. Adult onset | Possibility of first onset in adulthood: not low — in mild patients (FIX 5–40%), who account for about 30–40% of the total, it is common for abnormal bleeding to be first identified after age 18 without triggers such as surgery, tooth extraction, or trauma; severe cases (FIX < 1%) are mostly diagnosed in infancy and childhood; the FIX Leyden variant (spontaneous improvement after puberty) shows a unique course of transition from severe in childhood to mild in adulthood. |
| 1. History | In 1952, Biggs et al. first reported a new coagulation deficiency disease distinct from existing hemophilia, and the name 'Christmas disease' derives from the surname of the patient Stephen Christmas. |
| 2. Causes | Caused by decreased activity or amount of coagulation factor IX (FIX) due to various variants (point mutations, deletions, insertions, frameshifts, etc.) in the F9 gene located on the long arm of the X chromosome, Xq27.1. |
| 3. Genetics | X-linked recessive inheritance. The F9 gene is about 34 kb, 8 exons, 415 amino acids (55 kDa). A vitamin K-dependent protein composed of Gla, EGF, and protease domains. The Leyden variant (spontaneous improvement after puberty) and the Padua variant (used in gene therapy) are characteristic. |
| 4. Epidemiology | Affects 1 in 25,000–30,000 male births, accounting for about 20% of all hemophilia. An estimated 160,000 affected worldwide; about 750 with type B in the Korean hemophilia registry data (KBDR). |
| 5. Pathophysiology | FIX deficiency → inability to form the intrinsic tenase complex (FIXa-FVIIIa-Ca²⁺-phospholipid) → decreased FXa generation → thrombin deficiency → hemostatic failure. |
| 6. Symptoms | Severe: spontaneous hemarthrosis, muscle hematoma, intracranial hemorrhage. Moderate: excessive bleeding after trauma. Mild: delayed hemostasis after surgery or tooth extraction. The Leyden variant form transitions from severe in childhood to mild in adulthood. |
| 7. Signs | Isolated APTT prolongation, decreased FIX:C, normal PT, platelets, and bleeding time. Inhibitor incidence about 3–5%, markedly lower than in hemophilia A. |
| 8. Screening | FIX:C testing of newborns with a family history (retest at 6 months needed because normal values are low in the neonatal period), FIX:C measurement when APTT is prolonged, carrier F9 gene analysis. |
| 9. Diagnosis | Confirm APTT prolongation → FIX:C measurement (one-stage/chromogenic) → mixing test → inhibitor test → F9 gene analysis (Sanger or NGS) → promoter analysis when Leyden is suspected. |
| 10. Treatment | FIX concentrates (standard half-life and EHL products), emicizumab, fitusiran, gene therapy approved by the FDA in 2022 (etranacogene dezaparvovec/Hemgenix). |
| 11. Prognosis | Life expectancy at normal levels with modern prophylaxis. Low inhibitor incidence (3–5%), so prognosis is relatively good. Long-term efficacy of gene therapy under follow-up observation. |
| 12. Prevention | Genetic counseling, carrier F9 gene testing, prenatal diagnosis (CVS/amniocentesis), preimplantation genetic testing (PGT), prevention of arthropathy with early prophylaxis. |
| 13. References | Biggs R et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952 … and 9 other papers |
Records of a disease with a bleeding tendency in male lineages are very old in human history; the Talmud already contains a rule that brothers of boys who died of excessive bleeding at circumcision may be exempted from circumcision. This record is interpreted as describing hemophilia A and hemophilia B together without distinguishing them. The 12th-century Arab physician Albucasis also described families in the male line who died from even minor wounds. In the early 19th century, the American physician John Otto (1803) named hemophilia with the expression "bleeders" and first described its X-linked inheritance, and in the 1820s Schönlein first used the term 'Hämophilie'. However, all these early descriptions also did not distinguish hemophilia A from B, and until the mid-20th century the two diseases were recognized as a single disease.
In 1947, Alfredo Pavlovsky of Argentina observed the remarkable fact that mixing the plasma of two hemophilia patients corrected the clotting time. This observation was the first experimental evidence suggesting that hemophilia is not a single factor deficiency but can be caused by at least two or more different deficiencies. At the time, Pavlovsky did not fully grasp the clinical significance of this result, but it became the foundation on which a British research team developed this observation into a systematic study 5 years later.
On December 27, 1952, a paper titled "Christmas disease: a condition previously mistaken for haemophilia" was published in the British Medical Journal, co-authored by seven authors: Rosemary Biggs, A.S. Douglas, R.G. Macfarlane, J.V. Dacie, W.R. Pitney, C. Merskey, and J.R. O'Brien. In this paper, the authors described a new type of hemophilia in a series of patients, including Stephen Christmas, then a 5-year-old boy from Canada, in which clotting was corrected by mixing with the plasma of patients with existing hemophilia (hemophilia A, i.e., factor VIII deficiency). This correction experiment made it clear that the new disease was due to deficiency of a coagulation factor different from factor VIII. The name of the disease derives from 'Christmas', the surname of the first reported patient, and coinciding with the paper's publication in December, the Christmas season, the name became even better known. In the same year, in the same journal, almost simultaneously with the Biggs group, Aggeler et al. independently reported a similar deficient factor, naming it PTC (Plasma Thromboplastin Component), and the two names were used interchangeably for a while.
In 1952, Schulman and Simone named this new coagulation factor 'Factor IX (FIX)', and this name began to be used internationally. In 1964, when the waterfall/cascade model of coagulation was proposed by Macfarlane, Davie, and Ratnoff, the position of FIX in the intrinsic coagulation pathway became clear. In the 1970s, family studies in the Leiden region of the Netherlands discovered the FIX Leyden phenotype—a special form that is severe in childhood but spontaneously improves to mild as FIX expression increases under the influence of testosterone after puberty—which became an important milestone in coagulation biology. In 1982, Kurachi and Davie cloned the cDNA of human FIX, and in 1985 the entire genomic structure of the F9 gene (Xq27.1, 34 kb, 8 exons) was fully decoded.
Plasma-derived FIX concentrates were introduced into clinical practice from the 1960s–70s, but the contaminated blood scandal of the 1980s caused transfusion-transmitted HIV and HCV infections, bringing great tragedy to the hemophilia community. In reflection on this, recombinant FIX (BeneFIX, Nonacog alfa) was launched in 1998, opening an era of safe treatment without infection risk. As genetic research deepened after the 2000s, the FIX Padua variant (p.Arg338Leu) was identified as a gain-of-function variant—increasing the efficiency of the FXa-FIXa complex about 100-fold over normal—and the idea of using it in gene therapy vectors was proposed. After Nathwani et al. reported the clinical efficacy of AAV-based FIX gene therapy for the first time in the world in 2011, etranacogene dezaparvovec (Hemgenix, CSL Behring) received FDA approval in November 2022 and was listed as the first hemophilia B gene therapy. This innovative treatment shows a sustained effect at FIX:C levels of 30–40% with a single intravenous administration, opening a new chapter in the history of hemophilia B treatment.
Hereditary factor IX deficiency is an X-linked recessive genetic disease caused by pathogenic variants in the F9 gene located on the long arm of the X chromosome, Xq27.1. Because males (46,XY) have only one X chromosome, the disease manifests even if they carry only one variant allele. Females (46,XX) become carriers when only one of their two X chromosomes has a variant; most maintain normal FIX:C, but in some carriers—particularly when the proportion of normal X chromosomes is low due to random inactivation (lyonization)—FIX:C may be significantly decreased and mild bleeding symptoms may appear. Rarely, severe hemophilia B can manifest in women with Turner syndrome (45,X) or homozygous/heterozygous women.
Thousands of pathogenic variants have been reported in the F9 gene to date, and they are systematically registered in the HAMSTeRS (Haemophilia A and B Mutation, Structure, Test, and Resource Site) database. By variant type, point mutations (missense/nonsense) at about 84% are the most common, with missense variants making up the majority. Small deletions account for about 8%, small insertions about 3%, large deletions about 3%, and splicing variants about 2%. Whereas the main severe variant in hemophilia A is the F8 intron 22 inversion, inversions are rare in the F9 gene. In about 30% of all patients, new mutations (de novo mutations) give rise to patients without a family history.
FIX is a vitamin K-dependent serum protein synthesized in the liver. Glutamic acid residues in the Gla domain (gamma-carboxyglutamic acid domain) located at the N-terminus of the protein are converted to gamma-carboxyglutamic acid by a vitamin K-dependent carboxylase, and only when this process occurs normally can FIX bind to phospholipid membrane surfaces and form coagulation complexes. Therefore, in addition to F9 gene variants, FIX function can also decrease acquiredly with vitamin K antagonist (warfarin) administration or in vitamin K deficiency. However, unlike hereditary factor IX deficiency, these are acquired causes and are distinguished from gene variants. In patients with F9 variants, missense variants in the Gla domain impair phospholipid-binding ability, so functional activity may be greatly reduced even if the FIX protein is expressed normally.
FIX Leyden arises from point mutations located in the promoter region of the F9 gene (particularly variants such as -6G>A, -5G>A). This region contains an androgen hormone response element (AHRE), and normally after puberty testosterone binds to this site and increases FIX expression. In the Leyden variant, this response element is damaged, so FIX is hardly expressed in childhood, showing the phenotype of severe hemophilia B, but after puberty, as testosterone levels rise, FIX expression recovers by bypassing the damaged promoter or via other pathways, and FIX:C rises to the mild range. This is a unique spontaneous improvement phenotype observed only in hemophilia B, and is also a very unusual case molecular-biologically.
The F9 gene is located on the long arm of the X chromosome, Xq27.1, with a total length of about 34 kb, and consists of 8 exons. The mature protein consists of 415 amino acids, and its molecular weight is about 55 kDa, much smaller than FVIII (280 kDa), the causative protein in hemophilia A. This difference also affects half-life and product characteristics, so FIX concentrates have a significantly longer half-life than FVIII concentrates (about 18–24 hours vs about 12 hours).
The FIX protein is composed, from the N-terminus to the C-terminus, of the Gla domain - EGF1 domain - EGF2 domain - activation peptide - serine protease catalytic domain. The Gla domain (about 45 amino acids) contains 12 glutamic acid residues that are targets of vitamin K-dependent carboxylation and is essential for phospholipid membrane binding. The EGF1 domain is involved in interaction with FVIIIa and phospholipids, and the EGF2 domain contributes to binding with the FX substrate. The activation peptide is cleaved by FXIa or the FVIIa/tissue factor complex and released when FIX is activated to FIXa; because it is excreted in urine, it is sometimes used as an indicator of FIX activation. The serine protease catalytic domain contains the catalytic triad of His, Asp, and Ser, and is responsible for the enzymatic activity that cleaves FX as substrate to generate FXa.
The FIX Leyden variant is reported as point mutations (-6G>A, -5G>A, -4C>T, etc.) located in the F9 promoter region, particularly about 5–6 bp upstream of the transcription start site. This position overlaps the AHRE (androgen hormone response element), so when mutated, testosterone-induced transcription is impossible in childhood but partially recovers through other regulatory pathways after puberty. As a result, a severe phenotype with FIX:C <1% is seen in childhood, and in adulthood FIX:C rises to 20–60%, becoming mild hemophilia B.
The FIX Padua variant (p.Arg338Leu) is a gain-of-function variant first reported in a family from Padua, Italy, in which arginine 338 in the catalytic domain is replaced by leucine. This variant increases the efficiency of FIXa-FXa complex (intrinsic tenase) formation up to about 100-fold over normal, so that measured FIX:C greatly exceeds the normal range. This variant, which causes a thrombotic tendency, was paradoxically applied to gene therapy vectors; etranacogene dezaparvovec (Hemgenix) carries the FIX Padua (p.Arg338Leu) variant sequence in an AAV5 vector and is designed to stably raise FIX:C to about 30–40% of normal with a single administration.
It is X-linked recessive; carrier women on average maintain normal FIX:C, but due to skewed lyonization, FIX:C falls to 40% or below in some, who may show mild bleeding symptoms. Carrier confirmation is made by F9 gene analysis (Sanger sequencing of 8 exons or next-generation sequencing, NGS), and promoter variants (when Leyden is suspected) require additional analysis. About 30% of all patients arise from new mutations (de novo) without a family history, so if clinically suspected, genetic testing must be performed even without a family history.
Hereditary factor IX deficiency (hemophilia B) occurs with a frequency of 1 in 25,000–30,000 male births and accounts for about 20% of all hemophilia. It is about 4–5 times rarer than hemophilia A (factor VIII deficiency, 1 in 5,000–10,000). According to estimates by the World Federation of Hemophilia (WFH), about 160,000 people worldwide are affected by hemophilia B, but because diagnosis is insufficient in regions with weak medical infrastructure, the actual number of affected individuals is estimated to be higher. According to the Korean Bleeding Disorder Registry (KBDR), about 750 patients are registered with hemophilia B, of whom severe (FIX:C <1%) account for about 40–50%, moderate (1–5%) for about 10–15%, and mild (5–40%) for about 35–45%.
Hereditary factor IX deficiency is not limited to a particular race or ethnicity and occurs in all ethnic groups worldwide. Because it is X-linked, it occurs overwhelmingly in males, and female patients are rarely observed in Turner syndrome, homozygous/heterozygous women, or carriers with severely skewed lyonization. Cases in which the same F9 variant appears concentrated in certain regional populations due to a founder effect have been reported, but overall, differences in prevalence by ethnicity are not large.
Severity is classified according to the measured FIX:C value. Severe is defined as FIX:C <1 IU/dL (less than 1% of normal), moderate as 1–5 IU/dL, and mild as 5–40 IU/dL. Worldwide, about 30–45% of hemophilia B patients are estimated to be severe, 10–15% moderate, and 40–50% mild. The incidence of inhibitors (anti-FIX alloantibodies) is about 3–5%, markedly lower than the 25–30% in hemophilia A. However, a characteristic of hemophilia B is that when inhibitors develop, they are more often accompanied by hypersensitivity reactions (anaphylaxis) to FIX than in hemophilia A.
Blood coagulation is broadly divided into the extrinsic pathway (tissue factor pathway) and the intrinsic pathway (contact activation pathway), and both pathways ultimately converge into the common pathway to form a fibrin clot. FIX is a key component of the intrinsic pathway. When blood is exposed to negatively charged surfaces (collagen, tissue factor, etc.) after vascular injury, the contact activation pathway begins, activating FXIIa → FXIa → FIX in sequence. In addition, the FVIIa-tissue factor complex of the extrinsic pathway can also directly activate FIX, so FIX is also involved in the initial initiation of coagulation.
Activated FIXa by itself cannot efficiently activate FX. FIXa can efficiently convert FX to FXa only when it forms the intrinsic tenase complex together with the cofactor protein FVIIIa, divalent calcium ions (Ca²⁺), and a negatively charged phospholipid membrane (mainly the surface of activated platelets). Compared with the activity of FIXa alone, the intrinsic tenase complex is known to increase the efficiency of FX activation by about 100,000-fold (10⁵-fold) or more. When FIX is deficient, this complex cannot form, so FXa generation is extremely limited, the prothrombinase complex of the common pathway (FXa-FVa-Ca²⁺-phospholipid) cannot be sufficiently assembled, thrombin generation is drastically reduced, and consequently fibrin clot formation becomes insufficient, leading to hemostatic failure.
The mechanism by which recurrent spontaneous intra-articular bleeding (hemarthrosis) occurs in patients with severe hemophilia B has not been fully elucidated, but the rich vascular structure of the joint synovium and lack of local hemostatic capacity are cited as the main causes. When blood accumulates in the joint, synovial cells (synoviocytes) mount an inflammatory response, iron (Fe²⁺) induces oxidative stress, and repeated bleeding progresses to synovial thickening, cartilage destruction, and joint fibrosis, forming hemophilic arthropathy. Hemophilic arthropathy develops by the same mechanism in both hemophilia B and A, and minimizing the frequency of intra-articular bleeding with appropriate prophylaxis is the key to preventing arthropathy.
Patients with severe hemophilia B bleed spontaneously even without any obvious trauma. The most characteristic symptom is spontaneous hemarthrosis, which occurs frequently in large joints such as the knees, ankles, and elbows and is accompanied by pain, swelling, and limited motion. As intra-articular bleeding recurs, hemophilic arthropathy progresses and can lead to permanent joint deformity and dysfunction. Muscle hematoma is also common; in particular, iliopsoas hematoma can cause nerve palsy due to femoral nerve compression and requires emergency treatment. Intracranial hemorrhage is the most dangerous life-threatening complication and a major cause of death or permanent neurological damage. In the neonatal period, the disease is sometimes first detected through birth trauma, circumcision, or bleeding at blood sampling sites.
Moderate patients show excessive bleeding after minor trauma or procedures rather than spontaneous bleeding. Joint hematomas also occur but are less frequent than in severe disease and usually occur after trauma. Hemostasis is delayed after surgery, dental procedures, or relatively minor trauma, and when diagnosis is delayed, dangerous bleeding may be experienced during or after surgery.
Mild patients often have no bleeding symptoms during everyday activities, and abnormal bleeding may first be identified when there is a specific trigger such as surgery, tooth extraction, delivery, or trauma. For this reason, there are quite a few cases in which patients go undiagnosed until adulthood and are first diagnosed in adulthood due to excessive bleeding during surgery or dental procedures. Patients with the FIX Leyden variant show a severe phenotype in childhood, but after puberty FIX:C rises to the mild range, showing a unique course in which bleeding frequency becomes relatively low after reaching adulthood.
The most characteristic laboratory finding of hereditary factor IX deficiency is isolated prolongation of the activated partial thromboplastin time (APTT, aPTT). Thrombin time (TT), fibrinogen level, prothrombin time (PT/INR), platelet count, and bleeding time all remain within normal ranges. Because APTT evaluates the intrinsic and common pathways, it is prolonged when FIX is deficient, and the lower the FIX:C, the greater the prolongation. However, in mild patients, APTT may remain borderline or fall within the normal range, so direct FIX:C measurement is essential when clinically suspected. FIX:C is measured by one-stage clotting assay or chromogenic assay, and if results disagree between the two methods, the chromogenic assay may be more accurate.
In patients treated with FIX concentrates, when treatment response is poor or bleeding is difficult to control, development of an inhibitor (anti-FIX alloantibody) should be suspected. Inhibitors are quantified in Bethesda Units (BU) and classified as high titer (≥5 BU) and low titer (<5 BU). The incidence of inhibitors in hemophilia B is about 3–5%, much lower than in hemophilia A (25–30%). However, when an inhibitor develops in hemophilia B, anaphylactic reactions may accompany FIX infusion, so particular caution is needed. In patients with inhibitors, use of bypassing agents in place of FIX concentrates (activated prothrombin complex concentrate, aPCC; recombinant FVIIa) or switching to emicizumab is considered.
In joints with recurrent hemarthrosis, plain radiographs show findings of hemophilic arthropathy such as joint space narrowing, bone erosion, cystic changes, and joint deformity. Early and soft tissue changes can be evaluated more sensitively with ultrasound or MRI, which are useful for confirming the presence and degree of synovial thickening and joint effusion. Muscle hematomas can be diagnosed early by ultrasound, and intracranial hemorrhage is confirmed by CT or MRI.
When there is a family history of hemophilia B, early FIX:C testing is performed in newborns. However, neonatal FIX:C is measured lower than the adult normal range even in normal newborns, so caution is needed in interpretation. The FIX:C of full-term newborns is low, at about 15–50% of the adult normal value (50–150 IU/dL), and is even lower in the early neonatal period. For this reason, even if FIX:C is low in the neonatal period, it may be difficult to confirm hemophilia B, and retesting after 6 months of age is recommended. However, when severe or moderate hemophilia B is strongly suspected or there are clinical bleeding symptoms, treatment can be started under a provisional diagnosis based on low neonatal FIX:C.
When APTT is prolonged in an APTT test performed for other reasons and PT, platelet count, and fibrinogen are all normal, screening tests are performed for intrinsic pathway factors including FIX:C (factors VIII, IX, XI, XII, etc.). If APTT is corrected in a mixing test (1:1 mixing of patient plasma and normal plasma), factor deficiency is suggested; if not corrected, the presence of an inhibitor is suggested. If FIX:C is specifically low, hemophilia B is likely.
Determining carrier status in female family members such as the patient's mother, sisters, and daughters is essential for genetic counseling and family planning. Carrier confirmation is made by F9 gene analysis (Sanger sequencing or NGS), and FIX:C measurement alone makes it difficult to fully determine carrier status. Confirmed carrier women should have FIX:C measured before surgery regardless of bleeding symptoms, and if FIX:C is significantly low, bleeding prevention measures should be taken.
Diagnosis of hereditary factor IX deficiency proceeds in steps. The first step is confirmation of APTT prolongation. If APTT is prolonged and PT, TT, platelets, and fibrinogen are normal, intrinsic pathway factor deficiency or an inhibitor must be differentiated. The second step is FIX:C quantification. The one-stage clotting assay (activated partial thromboplastin time-based one-stage assay) is the standard, and the chromogenic substrate assay is used complementarily. Because discrepancies between the two methods may occur in some variants (especially Gla domain variants), comparing the results of both methods is recommended.
When FIX:C is measured low, a mixing test is performed to differentiate factor deficiency from an inhibitor. In factor deficiency, APTT is corrected immediately after mixing, whereas in the presence of an inhibitor it is not corrected or becomes prolonged again with prolonged incubation. Inhibitors are quantified by the Bethesda assay or the modified Nijmegen-Bethesda method.
F9 gene analysis is recommended for confirmation and genetic counseling. Methods use Sanger sequencing of all 8 exons and intron-exon junctions or a hemophilia panel NGS (next-generation sequencing). If no coding region variant is found, additional analysis including the promoter region (especially when FIX Leyden is suspected), 5'UTR, and 3'UTR is needed. Large deletions and duplications are confirmed by chromosomal array comparative genomic hybridization (array CGH) or multiplex ligation-dependent probe amplification (MLPA). Genetic analysis results are directly used for prognosis, inhibitor development risk, genetic counseling, and prenatal diagnosis.
Differentiation from other diseases showing isolated APTT prolongation is necessary. Hemophilia A (normal FIX:C, decreased FVIII:C), factor XI deficiency (hemophilia C, autosomal recessive), factor XII deficiency (no clinical bleeding), von Willebrand disease (especially type 2N, mixed type), and lupus anticoagulant (not corrected on mixing) are subject to differentiation. Differentiation is possible by factor-specific quantification and mixing tests.
The standard treatment for hereditary factor IX deficiency is administration of FIX concentrates. Plasma-derived (pdFIX) products include AlphaNine and Mononine, and recombinant (rFIX) standard half-life products include Benefix (Nonacog alfa) and Rixubis (Nonacog gamma). The half-life of FIX is about 18–24 hours, longer than that of FVIII (12 hours), so administration 1–2 times per week is sufficient for prophylaxis. Both on-demand treatment for bleeding episodes and prophylaxis aimed at preventing intra-articular bleeding can be given.
EHL (Extended Half-Life) products, which greatly extend half-life by applying Fc fusion, albumin fusion, or PEGylation technology to recombinant FIX, have been developed. The half-life of Alprolix (Eftrenonacog alfa, FIX-Fc fusion) is about 82 hours, allowing administration once weekly or once every other week. Idelvion (Albutrepenonacog alfa, FIX-albumin fusion) has a half-life of about 104 hours, allowing administration every other week or even once every 4 weeks. Rebinyn (Nonacog beta pegol, PEG-FIX) has a half-life of about 93 hours and likewise allows once-weekly administration. EHL products are evaluated as increasing patients' treatment adherence and quality of life by reducing the number of injections.
Emicizumab (Hemlibra) is a bispecific antibody that binds simultaneously to FIXa and FX, replacing FVIIIa-like function. It was originally developed for hemophilia A, but because it can also bridge FIXa and FX in hemophilia B patients with inhibitors and replace intrinsic tenase function, its indications are expanding to hemophilia B as well. It can be given by subcutaneous injection once weekly, every other week, or once every 4 weeks. Fitusiran is an RNAi therapy targeting antithrombin that increases thrombin generation by inhibiting antithrombin. It can be used in both hemophilia A and B, regardless of inhibitor status, and is administered by subcutaneous injection once a month.
Etranacogene dezaparvovec (Hemgenix, AMT-061), approved by the FDA in November 2022, is a gene therapy carrying a hepatocyte-specific promoter (ApoE-hAAT hybrid) and the FIX Padua (p.Arg338Leu) variant sequence in an AAV5 (adeno-associated virus serotype 5) vector. A phase 3 clinical trial (HOPE-B) confirmed that a single intravenous administration in adult patients with severe or moderate hemophilia B raises FIX:C to about 30–40% of normal and greatly reduces bleeding episodes. Long-term follow-up studies are under way, and safety issues such as the persistence of AAV in hepatocytes and liver enzyme elevation are being monitored.
When an inhibitor develops in hemophilia B, FIX concentrates are rendered ineffective, so bleeding is controlled using bypassing agents (aPCC or rFVIIa). Immune Tolerance Induction (ITI) shows a success rate of about 70–80% in hemophilia A, but in hemophilia B the success rate is low (about 30–40%) and there is a risk of anaphylaxis, so it is difficult to recommend. In hemophilia B patients with inhibitors, switching to emicizumab is currently the most preferred option.
Before the 1960s–70s, when there were no means of treatment, the life expectancy of patients with severe hemophilia B was so short that it was difficult for them to survive past their teens. As plasma transfusion, cryoprecipitate, and FIX concentrates were introduced in turn, survival improved dramatically; there was the tragedy of mass HIV and HCV infection due to the contaminated blood scandal of the 1980s–90s, but this risk has almost disappeared since the introduction of recombinant products. The life expectancy of hemophilia B patients receiving modern prophylaxis has improved to a level nearly equal to that of normal males. Minimizing the frequency of hemarthrosis with early prophylaxis can also prevent the development of hemophilic arthropathy, greatly improving quality of life and functional prognosis.
Inhibitor development can complicate treatment and worsen prognosis, but because its incidence in hemophilia B (3–5%) is much lower than in hemophilia A (25–30%), the overall prognosis is better. The higher risk of anaphylaxis when inhibitors develop compared with hemophilia A requires attention, and in this case switching to emicizumab is recommended over ITI. Long-term prognosis in patients who have received gene therapy is currently under follow-up observation, and loss of AAV due to hepatocyte division, immune responses, and hepatotoxicity remain variables that may affect long-term efficacy.
Most patients with severe hemophilia in the era before early prophylaxis began suffered severe hemophilic arthropathy. Currently, when prophylaxis is started early and FIX trough levels are kept high with EHL products or non-factor therapies, joint health is markedly improved. However, adult patients who already had joint damage before prophylaxis sometimes require joint replacement surgery. In addition, prompt treatment of acute complications such as intracranial hemorrhage, gastrointestinal bleeding, and nerve compression after muscle hematoma is important for long-term neurological prognosis.
Because hereditary factor IX deficiency is an X-linked recessive genetic disease, systematic genetic counseling for patients' families is essential. Carrier status in female family members such as the patient's mother, sisters, and daughters should be confirmed by F9 gene analysis (NGS or Sanger sequencing). Because FIX:C measurement alone has low sensitivity for carrier detection, genetic analysis is the basis. Women confirmed as carriers should receive information on prenatal diagnosis options before planning pregnancy, and consultation with a reproductive medicine specialist is recommended if needed.
When a carrier woman becomes pregnant, prenatal diagnosis of the fetus is possible. F9 gene analysis is performed on fetal cells by chorionic villus sampling (CVS) at 10–13 weeks of pregnancy or amniocentesis at 15–20 weeks. When the fetal sex is confirmed as male, testing for carriage of the variant allows prediction of hemophilia B. Preimplantation Genetic Testing (PGT) is a method of testing embryos for F9 variants before transfer during in vitro fertilization (IVF) and selectively transferring only normal or carrier embryos; it is an option for preventing the birth of a child with hemophilia B without termination of pregnancy.
In patients with severe hemophilia B, early prophylaxis is the most effective means of preventing hemophilic arthropathy. It is recommended to start prophylaxis before the first joint hematoma or before 2 years of age. Standard FIX concentrates are administered intravenously 1–2 times per week, and EHL products (Alprolix, Idelvion, etc.) can be given once every other week, reducing the burden of venous access in pediatric patients. With expanded hemophilia B indications for subcutaneous injectables such as emicizumab, the convenience of early prophylaxis is improving further. The goal of prophylaxis is to prevent spontaneous bleeding by maintaining FIX trough levels at 1–3 IU/dL or higher (or even higher).
For patients with hemophilia B, lifestyle habits that minimize bleeding risk are important. Avoid drugs that inhibit platelet function such as aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), and use subcutaneous or intravenous injection instead of intramuscular injection. Before surgery, tooth extraction, or procedures, the hematology department or hemophilia specialist team must be contacted to establish a plan for advance FIX administration. Because exercise helps maintain joint health, low-impact exercise such as swimming and cycling is recommended, and contact sports and activities with a high risk of trauma are restricted.